New Phase 3 trials registered, week of November 2, 2026: 3 industry trials
Industry sponsors registered 3 Phase 3 trials on ClinicalTrials.gov so far in the week of November 2 to 8, 2026. They plan to enroll 25,884 participants in all; the largest, Guangzhou Patronus Biotech's LYB005 trial, plans to enroll 25,000.
Compiled by code from the stream briefs and public records linked below; no model wrote this page. How we use automation
Each line below links the stream brief and the trial's ClinicalTrials.gov record, largest trial first.
This page updates as the week's records arrive. The week ends on Sunday, November 8, 2026.
The trials
- Guangzhou Patronus registers Phase III trial of LYB005 RSV vaccine in older adults. Sponsor: Guangzhou Patronus Biotech Co., Ltd. Conditions: Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus (RSV) Infection, RSV Vaccine. Intervention: LYB005. Phase: Phase 3. Planned enrollment: 25,000. Planned primary completion: September 2027. First posted November 2, 2026. Record: NCT07908654.
- Merck registers Phase 3 trial of Gocatamig with Durvalumab in small cell lung cancer. Sponsor: Merck Sharp & Dohme LLC. Condition: Small Cell Lung Cancer. Interventions: Gocatamig, Durvalumab, Rescue Medications. Phase: Phase 3. Planned enrollment: 564. Planned primary completion: December 2031. First posted November 2, 2026. Record: NCT07908537.
- Keymed registers Phase 3 trial of CM336+CM313 in relapsed multiple myeloma. Sponsor: Keymed Biosciences Co.Ltd. Condition: Multiple Myeloma (MM). Interventions: CM336, CM313, Daratumumab, Pomalidomide, Dexamethasone. Phase: Phase 3. Planned enrollment: 320. Planned primary completion: May 2030. First posted November 2, 2026. Record: NCT07910903.
By the numbers
- Trials: 3, from 3 lead sponsors.
- Planned enrollment: 25,884 in all across 3 trials; median 564 per trial.
- Largest: Guangzhou Patronus Biotech's LYB005 trial, 25,000. Smallest: Keymed Biosciences Co.Ltd's CM336 trial, 320.
- Phases as registered: 3 Phase 3.
- Planned primary completion: from September 2027 to December 2031.
How this page is made
Code builds this page from the stream briefs linked above and from each trial's ClinicalTrials.gov record, read when the page was last built: sponsor, condition, intervention, phase and enrollment come from the record. No model writes this page. Planned figures are the sponsor's estimates at registration.